Sunday, 16 December 2018

Aurobindo Pharma to acquire Australian firm's product

14 November 2018 | News

Melbourne-based Advent Pharmaceuticals is engaged in developing and commercialising generic inhaled medicines for global markets.

Representative Image

Representative Image

Aurobindo Pharma has said it's wholly-owned subsidiary has entered into an agreement to acquire a product under development and related assets from Australia-based Advent Pharmaceuticals Pty Ltd for $12.5 million.

"Our wholly-owned subsidiary, Aurobindo Pharma USA Inc., USA, has entered into an agreement to acquire a product under development and related assets from Advent Pharmaceuticals Pty Ltd, Australia, through AuroScience Pty Limited, Melbourne, a 100 per cent subsidiary of Aurobindo Pharma USA Inc, USA," a regulatory filing from Aurobindo said Monday.

Based out of Melbourne, Advent Pharmaceuticals is engaged in developing and commercialising generic inhaled medicines for global markets.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account





Survey Box

Does Indian Pharma lack an innovation-friendly ecosystem?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls